These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 2860267)

  • 1. Oxidation phenotype and the metabolism and action of beta-blockers.
    Lennard MS
    Klin Wochenschr; 1985 Apr; 63(7):285-92. PubMed ID: 2860267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS; Tucker GT; Woods HF
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.
    Lennard MS; Tucker GT; Silas JH; Woods HF
    Xenobiotica; 1986 May; 16(5):435-47. PubMed ID: 2874665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphic metabolism of beta-adrenoceptor antagonists.
    Silas JH; Lennard MS; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):11S-19S. PubMed ID: 6146335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.
    Smith RL
    Eur J Clin Pharmacol; 1985; 28 Suppl():77-84. PubMed ID: 2865154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
    McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The genetic control of bufuralol metabolism in man.
    Dayer P; Balant L; Courvoisier F; Kupfer A; Kubli A; Gorgia A; Fabre J
    Eur J Drug Metab Pharmacokinet; 1982; 7(1):73-7. PubMed ID: 6121708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
    Lennard MS; Silas JH; Freestone S; Trevethick J
    Br J Clin Pharmacol; 1982 Aug; 14(2):301-3. PubMed ID: 6125207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.
    Lewis RV; Lennard MS; Jackson PR; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1985 Mar; 19(3):329-33. PubMed ID: 2859048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.
    Lennard MS; Jackson PR; Freestone S; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984 Jun; 17(6):679-85. PubMed ID: 6743465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation.
    Minder EI; Meier PJ; Müller HK; Minder C; Meyer UA
    Eur J Clin Invest; 1984 Jun; 14(3):184-9. PubMed ID: 6147254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of verapamil in combination with atenolol, metoprolol and propranolol.
    Warrington SJ; Holt D; Johnston A; Fitzsimons TJ
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):37S-44S. PubMed ID: 6146339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.
    Dayer P; Balant L; Kupfer A; Striberni R; Leemann T
    Eur J Clin Pharmacol; 1985; 28(3):317-20. PubMed ID: 2861095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative review of beta-blocking agents.
    Jackson EA; Sullman SA
    Conn Med; 1984 Apr; 48(4):213-5. PubMed ID: 6143648
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.
    Laurent-Kenesi MA; Funck-Brentano C; Poirier JM; Decolin D; Jaillon P
    Br J Clin Pharmacol; 1993 Dec; 36(6):531-8. PubMed ID: 12959269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.
    Gangji D; Juvent M; Niset G; Wathieu M; Degreve M; Bellens R; Poortmans J; Degre S; Fitzsimons TJ; Herchuelz A
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):29S-35S. PubMed ID: 6146337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic and pharmacokinetic studies on bufuralol in man.
    Pringle TH; Francis RJ; East PB; Shanks RG
    Br J Clin Pharmacol; 1986 Nov; 22(5):527-34. PubMed ID: 2878678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. beta-Adrenoceptor antagonists: new drugs and new indications.
    Koch-Weser J; Frishman WH
    N Engl J Med; 1981 Aug; 305(9):500-6. PubMed ID: 6114433
    [No Abstract]   [Full Text] [Related]  

  • 20. Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol.
    Dayer P; Leemann T; Marmy A; Rosenthaler J
    Eur J Clin Pharmacol; 1985; 28(2):149-53. PubMed ID: 2859203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.